Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Out of curiosity, is Nemesis18 aka whosleftholdindabag a nice boss?
The reason I am asking is that Nemesis18 always likes his minions' posts over weekend. Nemesis18 must force his minions to work a lot over weekend.
George,
Safety is always over convince. Don't think the dark forces have no soul and they corrupt the system. Should Harvard do some background check on Ken Griffin before taking his money? Obviously not.
NWBO longs are complaining about low share price. I think if 10% or 25% of retailers start holding certificate the sp could take off right away.
Now I start thinking that you may be a wolf in sheep skin.
NWBO longs should take this post seriously. If you believe the system is working, the system may fail you in the end. Seriously, if the system were working, DCVax-L should have been available long time ago and tens of thousands of lives, especially many children's lives could have been saved. What kind of huge stakes could possibly make Harvard professor abandon ethic rules and write a hitting piece published on the Thanksgiving day?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174269450
Does everyone know the meaning of Fails-to-deliver?
https://www.sec.gov/comments/s7-07-23/s70723-20162302-331156.pdf
senti,
The biggest concern should be safety. You aren't saying no broker will take paper certificates, are you? If Schwab will not take them, we can always find another one.
BB,
Thank you for the reminder.
Sorry, my English is probably on elementary school level. If you say something deep, put it as simple as possible.
senti,
What are you talking about? You don't think we know this. Level with me: Do we have security for our shares at least if we do what BB suggested?
Cannot you sense how low these dark forces? Their lawyers even had the audacity using vacation as excuse. These dark forces pushed NWBO to the OTC in the thought that the company would become extinct sooner or later and all their dirty records would disappear without trace. You don't think there are enormous number of fake shares?
Let me ask you a quick question: Did you try it with Fidelity?
You forgot your stamp word "mate". Can you find anyone else uses that word as frequently as you on this board?
When I have time, I'll go through all your posts to see if I can find anything that might intrigue Laura Posner even more.
You need to find a new lawyer.
So you received DCVax-L treatment in 2015. You are still alive. For GBM patients, long-term mortality is nearly 100%. That's why there are only two or three meta-analysis on GBM patients simply because very few GBM patients can live over five or ten years. Have you been on follow-up check?
It should be easy for Laura Posner to go through NWBO data-base to find out who are the patients receiving the treatment in 2015. If you are poor minion, I have no interest. But you could be a billionaire, I suspect all NWBO retailers would appreciate my work if I help Laura Posner to hit the jackpot. You should have taken seriously the post by Red_Right_Hand right after you registered the new alias.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173970623
How about we let her decide on her own? If you are a paralegal working for her, then I agree with you.
Found the contact of Cohen Milstein. NWBO longs, send to Laura Posner anything you feel suspicious. IMO, there could be very rich basher roaming on this board. Cohen Milstein works on contingency basis and we don't need to pay a penny.
https://www.cohenmilstein.com/wp-content/uploads/2022/12/2nd-Amended-Complaint-NWBO-03182024.pdf
Laura H. Posner
Michael B. Eisenkraft
COHEN MILSTEIN SELLERS & TOLL PLLC
88 Pine Street, 14th Floor
New York, New York 10005
Tel: (212) 838-7797
Fax: (212) 838-7745
lposner@cohenmilstein.com
meisenkraft@cohenmilstein.com
Raymond M. Sarola (RS1010)
Cohen Milstein Sellers & Toll PLLC
100-120 N. 18th Street, Suite 1820
Philadelphia, PA 19103
Tel: (267) 479-5700
Fax: (267) 479-5701
rsarola@cohenmilstein.com
I didn't find the word "mate" in your post. Don't forget it next time.
This Nemesis18 claimed that he used to be in military and also work as inspector for the government.
When I confronted him, he gave me a response which seems like from a lawyer. I don't think a normal minion could afford a lawyer. Then who Nemesis18 really is. IMO, he is whosleftholdindabag. He may be the one who hired all the minions. Last time I was told he was as rich as Thermo. I list the information and you can make your judgement. Note whosleftholdindabag likes using the word "mate".
Again we do have a counsel free of charge and whosleftholdindabag is billionaire last time I heard. Will someone be so nice and put the counsel's contact here?
My perception of reality is absolute lunacy? Really?
Well, tell me if my perception of the following reality is lunatic too.
You are whosleftholdindabag who is rich on the level of Thermo magnitude. Are you the one who hired all the minions spreading lies and fabrications 24/7 on this board.
Dude,
You really surprised me. I thought you were just a hired minion. It turns out you could be the boss behind all those minions. The words you put here are from your lawyer. Did I get that right?
What you did convince me even more that you never joined the military and here you made up lies to deceive the NWBO retailers. You were not an inspector who used to work for government either. You are most likely a billionaire who may long NVCR and short NWBO.
RNA sequencing plays a crucial role in immunotherapy in several ways:
What is an ELISA (enzyme-linked immunosorbent assay)?
ELISA (enzyme-linked immunosorbent assay) is a plate-based assay technique designed for detecting and quantifying soluble substances such as peptides, proteins, antibodies, and hormones. Other names, such as enzyme immunoassay (EIA), are also used to describe the same technology. In an ELISA, the antigen (target macromolecule) is immobilized on a solid surface (microplate) and then complexed with an antibody that is linked to a reporter enzyme. Detection is accomplished by measuring the activity of the reporter enzyme via incubation with the appropriate substrate to produce a measurable product. The most crucial element of an ELISA is a highly specific antibody-antigen interaction.
Merck
Principal Scientist (R5), Biologics Analytical Research & Development (B-AR&D)
https://www.linkedin.com/jobs/view/principal-scientist-r5-biologics-analytical-research-development-b-ar-d-at-merck-3870456378/
Amgen
Sr. Scientist - Soluble Biomarker Laboratory, Clinical Assay Development
https://careers.amgen.com/en/job/south-san-francisco/sr-scientist-soluble-biomarker-laboratory-clinical-assay-development/87/63840080032
AstraZeneca
Development Scientist I, Analytical Development and Clinical Quality Control
https://careers.astrazeneca.com/job/new-haven/development-scientist-i-analytical-development-and-clinical-quality-control/43991/63787224256
GSK
Scientific Investigator Immune Cell Biology
https://jobs.gsk.com/en-us/jobs/394281?lang=en-us&previousLocale=en-US
Gilead
Associate Scientist, Protein Therapeutics
https://www.linkedin.com/jobs/view/associate-scientist-protein-therapeutics-at-gilead-sciences-3807392096/
Regeneron
Associate Scientist- Immunization
https://www.biospace.com/job/2894613/associate-scientist-immunization
Roche
Cellular Assay Associate/Scientist Oligonucleotides (m/f/d)
https://www.talentify.io/job/cellular-assay-associatescientist-oligonucleotides-mfd-basel-basel-stadt-roche-202211-140239
AbbVie
Senior Scientist II
https://careers.abbvie.com/en/job/senior-scientist-ii-in-worcester-ma-jid-1099
Eli Lilly
Senior Technician, In vivo pharmacology, Discovery Technologies
https://careers.lilly.com/us/en/job/R-63004/Senior-Technician-In-vivo-pharmacology-Discovery-Technologies
Takeda
Research Scientist II, Inflammation Discovery Research
https://www.linkedin.com/jobs/view/research-scientist-ii-inflammation-discovery-research-at-takeda-3783144631/
BMS
Senior Scientist, QC Training Program Lead
https://bristolmyerssquibb.wd5.myworkdayjobs.com/en-US/BMS/job/Devens---MA---US/Senior-Scientist--QC-Program-Lead_R1579472
This is the board for adults not for elementary school student. Finish elementary school and you can come back when you can write a complete sentence.
How much are you paid each day to post nonsense? You do know Cohen Milstein must collect all the possible evidence related to the lawsuit, don't you?
Flattered.
You know LP used to be the board member of M2gen (Aster Insights) for eight years. She withdrew from M2gen board and Merck formed the partnership with M2gen. In the current combo trial, NWBO is not among the collaborators. The collaboration trial has been off the radar for over eight years. You see what they were doing. Merck and NWBO are trying to disconnect in public as possible as they can for now.
https://www.biospace.com/article/releases/m2gen-announces-that-merck-and-co-joins-the-b-oncology-research-information-exchange-network-orien-b-avatar-research-program-/
https://www.prnewswire.com/news-releases/cdr-merck-ghi-and-mckesson-ventures-invest-in-innovative-oncology-data-and-informatics-company-m2gen-301249522.html
https://www.asterinsights.com/
Don't give them credit. If they were smart, they would not join dark forces doing something potentially being prosecuted.
You haven't answered my question: Are you impersonating as former military member to cheat investors of NWBO for personal financial gains? Is this act a crime in UK?
You are no solider. Your despicable behavior is an insult on the good name of the military. Keep playing your little dirty game.
Navigating the Landscape of Precision Medicine in Gastric Cancer: FGFR2b Protein Overexpression as an Emerging Biomarker
https://www.amgen.com/stories/2024/04/navigating-the-landscape-of-precision-medicine-in-gastric-cancer
https://gastriccancer.org/about-us/partners-sponsors/
Gary,
Would you agree DCVax-L is revolutionary? If it is revolutionary, any BP who owns DCVax-L could be the target for market monopoly investigation.
Take a look at all the BPs. Each one of them has acquisitions on ADCs and t-cell engagers. They are all for precision medicines. Here is what Amgen put on its webpage. Amgen claimed that now they have the knowledge and tools to identify the targets that precision medicines can carry. I found nearly all the BPs were hiring people to do target identification job. I suspect it has something to do with DCVax-L.
Horse,
I am not sure about BO from a BP since I am afraid that BP's pocket is not deep enough. As for share price, I have no clue. What I do know is that if Merck gets the platform from NWBO, others will follow. We can see right after Merck signed the ADC deal, all the other BPs become crazy. Merck had the t-cell engager acquisition once Merck found all the other BPs have t-cell engager in their portfolio.
In fact, I feel sorry for those bashers. Why not do the right thing and get rich?
Horse,
Hold NWBO until the company starts issuing dividends if you don't have the necessity to cash it.
For those who have insidious motives, here is something you need to pay special attention.
The following is the official address of Oncovir according to linkedin. It is a home office. The owner of Oncovir sold his house for $2.4m in 2021 and currently pays rent. Who would sold his house for something whose patent is expired already? I suspect the things about to happen must be enormous otherwise it cannot explain why the owner would sell his beautiful house for it.
https://www.linkedin.com/company/oncovir/about/
Quick question:
Is it a crime in UK for someone impersonating as a former military member for financial gains? I suspect it is.
Professor Esteban Celis is Scientific Advisor of Oncovir who wrote plenty papers with Dr. Dmitry Gabrilovich--Chief Scientist, Cancer Immunology at AstraZeneca. Note that Dr. Dmitry Gabrilovich is an expert on dendritic cells too. The following are some of the papers they wrote together. I suspect the list is more persuasive than the fact that AZN's headquarter is close to Sawston manufacturing facility.
https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/tumour-microenvironment.html
Peroxynitrite in the tumor microenvironment changes the profile of antigens allowing escape from cancer immunotherapy
https://www.cell.com/cancer-cell/pdf/S1535-6108(22)00393-2.pdf
HIF-1a regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment
https://rupress.org/jem/article/207/11/2439/40663/HIF-1-regulates-function-and-differentiation-of
Lipid accumulation and dendritic cell dysfunction in cancer
https://www.nature.com/articles/nm.2172
Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice
https://www.jci.org/articles/view/40269
Mechanism of T Cell Tolerance Induced by Myeloid-Derived Suppressor Cells
https://journals.aai.org/jimmunol/article/184/6/3106/82771
Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice
https://www.jci.org/articles/view/45862
ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R–mediated apoptosis
https://www.jci.org/articles/view/74056
Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer
https://www.nature.com/articles/s41467-017-02186-9
Consensus nomenclature for CD8+ T cell phenotypes in cancer
https://www.tandfonline.com/doi/full/10.1080/2162402X.2014.998538
Autophagy Induced by Conventional Chemotherapy Mediates Tumor Cell Sensitivity to Immunotherapy
https://aacrjournals.org/cancerres/article/72/21/5483/576215/Autophagy-Induced-by-Conventional-Chemotherapy
Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17–producing CD4+ T cells
https://rupress.org/jem/article/212/3/351/41764/Immature-myeloid-cells-directly-contribute-to-skin
ER stress response regulates the fate of myeloid-derived suppressor cells through TRAIL receptors mediated apoptosis (TUM4P.907)
https://journals.aai.org/jimmunol/article/192/1_Supplement/138.8/53853
Abstract 5599: Novel mechanism of synergistic effect of cancer immunotherapy and chemotherapy
https://aacrjournals.org/cancerres/article/70/8_Supplement/5599/566350/Abstract-5599-Novel-mechanism-of-synergistic
Here is the new board member of Oncovir. When did he join the company? Was that around the time the JAMA paper was submitted? For those on the other side of the fence, without doubt, you are going to lose. It is just the matter of how pathetic your loss is. I suspect it is going to huge. I have Boma available free of charge for those who are homeless.
Here are all the clinical trials related to poly-iclc. Has anyone gone through the list? I have and I even read some of the papers related to some of the trials. As a matter of fact, the patent of poly-iclc expired last year without any FDA approval after so many trials.
https://classic.clinicaltrials.gov/ct2/results?cond=&term=Poly-ICLC&type=&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&locn=&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=
But the President of Oncovir made the claim that 2024 would be a breakthrough year for Oncovir. The exciting part is that we will see how exciting it is probably in one month. My reasoning for one month is that he said additional data on t cell expansion and infiltration would come in the next few weeks. One month after his post, Oncovir released AACR present on prostate cancer. I suspect data on DCVax-L in combination with poly-iclc should be the next.
This is the webpage from Institute for Immunology at Mainz. This is the core research of the institution. Does the description look familiar? The interesting part is that this webpage was setup on June 10, 2018 according to WayBackMachine and remains unchanged ever since. Don't be surprised if there is another paper. Recall the following paper only dealing with a specific subtype of rectal cancer which accounts for about 3% of rectal cancer. The paper from the collaboration trial if there is one is going to be in limelight.
https://www.mskcc.org/news-releases/asco-2022-100-complete-response-rate-mmrd-locally-advanced-rectal-cancer-seen-pivotal-immunoablative-neoadjuvant-immunotherapy-clinical-trial
Thanks, starric.
The version of DC vaccine developed by Italian researchers is just for research purpose. They started treating melanoma since 2001 and I am really surprised that they haven't included poly-iclc in their formulation. No way can be compared with what we have.
SWOG (formerly the Southwest Oncology Group) is a National Cancer Institute (NCI) supported organization that conducts clinical trials in adult cancers. For the past several years, SWOG has been using different combinations of almost all the FDA approved drugs for trials on various types of cancers. Has anyone heard any breakthrough from these trials?
The group chair of SWOG--Dr. Charles D. Blanke wrote a bunch of papers with Dr. Monica Bertagnolli. Did they know the efficacy of DCVax-L? If they knew, why did they run all the following trials? Why not choose DCVax-L directly?
https://www.swog.org/about/who-leads-swog-cancer-research-network
https://scholar.google.com/scholar?hl=en&as_sdt=0%2C44&q=Charles+Blanke+%2B+Monica+Bertagnolli&btnG=
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)
https://classic.clinicaltrials.gov/ct2/show/NCT04071457?recrs=ab&lead=swog&draw=2&rank=26
Daratumumab -- Janssen Biotech, Inc.
Lenalidomide -- Bristol Myers Squibb
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
https://classic.clinicaltrials.gov/ct2/show/NCT04205968?recrs=ab&lead=swog&draw=2&rank=24
Paclitaxel -- Bristol-Myers Squibb
Ramucirumab -- Eli Lilly
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial (PROBE)
https://classic.clinicaltrials.gov/ct2/show/NCT04510597?recrs=ab&lead=swog&draw=2&rank=21
Nivolumab -- Bristol-Myers Squibb
Pembrolizumab -- Merck
Avelumab -- Merck KGaA and Pfizer
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
https://classic.clinicaltrials.gov/ct2/show/NCT04511013?recrs=ab&lead=swog&draw=2&rank=20
Binimetinib -- Pfizer
Encorafenib -- Pfizer
Ipilimumab -- Bristol-Myers Squibb
Nivolumab -- Bristol-Myers Squibb
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT04625647?recrs=ab&lead=swog&draw=2&rank=19
Sotorasib -- Amgen
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
https://classic.clinicaltrials.gov/ct2/show/NCT04647916?recrs=ab&lead=swog&draw=2&rank=18
Sacituzumab Govitecan -- Gilead
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
https://classic.clinicaltrials.gov/ct2/show/NCT05040360?recrs=ab&lead=swog&draw=2&rank=15
Capecitabine -- Roche
Temozolomide -- Merck
Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer
https://classic.clinicaltrials.gov/ct2/show/NCT05364645?recrs=ab&lead=swog&draw=2&rank=14
Pemetrexed -- Eli Lilly
Selpercatinib -- Eli Lilly
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
https://classic.clinicaltrials.gov/ct2/show/NCT05561387?recrs=ab&lead=swog&draw=2&rank=12
Bortezomib -- Takeda
Daratumumab and Hyaluronidase-fihj -- Johnson & Johnson
Lenalidomide -- Bristol-Myers Squibb
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
https://classic.clinicaltrials.gov/ct2/show/NCT05633602?recrs=ab&lead=swog&draw=2&rank=10
Pembrolizumab -- Merck
Ramucirumab -- Eli Lilly
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
https://classic.clinicaltrials.gov/ct2/show/NCT05633615?recrs=ab&lead=swog&draw=2&rank=9
Axicabtagene Ciloleucel -- Gilead
Lisocabtagene Maraleucel -- Bristol-Myers Squibb
Tisagenlecleucel -- Novartis
Polatuzumab Vedotin -- Roche
Mosunetuzumab -- Roche
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT05642572?recrs=ab&lead=swog&draw=2&rank=8
Capmatinib -- Novartis
Osimertinib -- AstraZeneca
Ramucirumab -- Eli Lilly
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
https://classic.clinicaltrials.gov/ct2/show/NCT05806515?recrs=ab&lead=swog&draw=2&rank=6
Carboplatin -- Bristol-Myers Squibb
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
https://classic.clinicaltrials.gov/ct2/show/NCT05890352?recrs=ab&lead=swog&draw=2&rank=5
Lenalidomide -- Bristol-Myers Squibb
Tafasitamab -- Incyte
Tazemetostat -- Ipsen
Zanubrutinib -- BeiGene
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
https://classic.clinicaltrials.gov/ct2/show/NCT05929768?recrs=ab&lead=swog&draw=2&rank=4
Carboplatin -- Bristol-Myers Squibb
Paclitaxel -- Bristol-Myers Squibb
Pembrolizumab -- Merck
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT06031688?recrs=ab&lead=swog&draw=2&rank=2
Ramucirumab -- Eli Lilly
Tepotinib -- Merck KGaA
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT06116682?recrs=ab&lead=swog&draw=2&rank=1
Amivantamab -- Janssen and Genmab
Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT04268550?recrs=bd&lead=swog&draw=2&rank=6
Selpercatinib -- Eli Lilly
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT05096663?recrs=bd&lead=swog&draw=2&rank=4
Nogapendekin Alfa -- ImmunityBio
Pembrolizumab -- Merck
Ramucirumab -- Eli Lilly
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT06116682?recrs=bd&lead=swog&draw=2&rank=1
Amivantamab -- Janssen and Genmab
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT06031688?recrs=bd&lead=swog&draw=2&rank=2
Ramucirumab -- Eli Lilly
Tepotinib -- Merck KGaA